Clinical Trial Update: A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a DNA vaccine delivered by electroporation for the prevention of influenza caused by H1 and H5 viruses; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza H1n1
• Influenza H5n1

Drugs mentioned

• DNA vaccine with electroporation (Inovio Pharmaceuticals)

Snippet

Sponsor: Inovio Pharmaceuticals | Conditions: Healthy | Phase 1 | Status: COMPLETED